| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000021877 |
| Receipt No. | R000025222 |
| Official scientific title of the study | Basic analysis of vitreous fluid and retina for chorioretinal disorders |
| Date of disclosure of the study information | 2016/04/14 |
| Last modified on | 2016/04/11 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Basic analysis of vitreous fluid and retina for chorioretinal disorders | |
| Title of the study (Brief title) | Basic analysis of vitreous fluid and retina | |
| Region |
|
|
| Condition | ||
| Condition | chorioretinal disorders includins uveitis, retinal detachment, or diabetic retinopathy | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the pathogenesis of chorioretinal disorders by the analysis of ocular tissues. |
| Basic objectives2 | Others |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Inflammatory cytokine levels, flow cytometric analysis, PCR, and immunohistochemical analysis of intraocular tissues. |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with chorioretinal disorders includins uveitis, retinal detachment, or diabetic retinopathy. | |||
| Key exclusion criteria | Patients who is determined inappropriate to participate in this study by attending physician. | |||
| Target sample size | 500 | |||
| Research contact person | |
| Name of lead principal investigator | Chie Sotozono |
| Organization | Kyoto Prefectural University of Medicine |
| Division name | Department of Ophthalmology |
| Address | 465 Kajii-cho, Kamigyo-ku, Kyoto city, Kyoto 602-0841, Japan |
| TEL | 075-251-5578 |
| csotozon@koto.kpu-m.ac.jp | |
| Public contact | |
| Name of contact person | Kenji Nagata |
| Organization | Kyoto Prefectural University of Medicine |
| Division name | Department of Ophthalmology |
| Address | 465 Kajii-cho, Kamigyo-ku, Kyoto city, Kyoto 602-0841, Japan |
| TEL | 075-251-5578 |
| Homepage URL | |
| kenji68@koto.kpu-m.ac.jp | |
| Sponsor | |
| Institute | Kyoto Prefectural University of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 京都府立医科大学附属病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | We demonstrated that CD4/CD8 ratio of vitreous-infiltrating lymphocytes has high diagnostic value in ocular sarcoidosis. |
| Other related information | prospective study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000025222 |